Clinical trial
Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study…
NCT00041613 · Introgen Therapeutics, Industry · Unknown status
Key facts
| NCT number | NCT00041613 |
|---|---|
| Title | Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate |
| Lead sponsor | Introgen Therapeutics, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Squamous Cell |
| Intervention type | Genetic |
| Interventions | INGN 201 |
| First posted | Jul 12, 2002 |
| Last update posted | Apr 1, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: